301 related articles for article (PubMed ID: 19787255)
21. Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis.
Cory AH; Chen J; Cory JG
Anticancer Res; 2006; 26(2A):1289-95. PubMed ID: 16619536
[TBL] [Abstract][Full Text] [Related]
22. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.
Puca R; Nardinocchi L; Porru M; Simon AJ; Rechavi G; Leonetti C; Givol D; D'Orazi G
Cell Cycle; 2011 May; 10(10):1679-89. PubMed ID: 21508668
[TBL] [Abstract][Full Text] [Related]
23. PRIMA-1 induces caspase-mediated apoptosis in acute promyelocytic leukemia NB4 cells by inhibition of nuclear factor-κB and downregulation of Bcl-2, XIAP, and c-Myc.
Farhadi E; Safa M; Sharifi AM; Bashash D
Anticancer Drugs; 2017 Jan; 28(1):51-58. PubMed ID: 27548348
[TBL] [Abstract][Full Text] [Related]
24. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
[TBL] [Abstract][Full Text] [Related]
25. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.
Orue A; Chavez V; Strasberg-Rieber M; Rieber M
BMC Cancer; 2016 Nov; 16(1):902. PubMed ID: 27863474
[TBL] [Abstract][Full Text] [Related]
26. PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins.
Rökaeus N; Klein G; Wiman KG; Szekely L; Mattsson K
Oncogene; 2007 Feb; 26(7):982-92. PubMed ID: 16909106
[TBL] [Abstract][Full Text] [Related]
27. A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts.
Liang Y; Mafuvadze B; Besch-Williford C; Hyder SM
Breast Cancer (Dove Med Press); 2018; 10():53-67. PubMed ID: 29606888
[TBL] [Abstract][Full Text] [Related]
28. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
Cuddihy AR; Jalali F; Coackley C; Bristow RG
Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
[TBL] [Abstract][Full Text] [Related]
29. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
Bykov VJ; Issaeva N; Shilov A; Hultcrantz M; Pugacheva E; Chumakov P; Bergman J; Wiman KG; Selivanova G
Nat Med; 2002 Mar; 8(3):282-8. PubMed ID: 11875500
[TBL] [Abstract][Full Text] [Related]
30. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
Saha MN; Jiang H; Yang Y; Reece D; Chang H
Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
[TBL] [Abstract][Full Text] [Related]
31. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion.
Nahi H; Merup M; Lehmann S; Bengtzen S; Möllgård L; Selivanova G; Wiman KG; Paul C
Br J Haematol; 2006 Jan; 132(2):230-6. PubMed ID: 16398657
[TBL] [Abstract][Full Text] [Related]
32. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database.
Bykov VJ; Issaeva N; Selivanova G; Wiman KG
Carcinogenesis; 2002 Dec; 23(12):2011-8. PubMed ID: 12507923
[TBL] [Abstract][Full Text] [Related]
33. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.
Rangel LP; Ferretti GDS; Costa CL; Andrade SMMV; Carvalho RS; Costa DCF; Silva JL
J Biol Chem; 2019 Mar; 294(10):3670-3682. PubMed ID: 30602570
[TBL] [Abstract][Full Text] [Related]
34. Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.
Xiao G; Annor GK; Fung K; Keinänen O; Zeglis BM; Bargonetti J
Mol Pharm; 2021 Jan; 18(1):338-346. PubMed ID: 33289569
[TBL] [Abstract][Full Text] [Related]
35. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Weinmann L; Wischhusen J; Demma MJ; Naumann U; Roth P; Dasmahapatra B; Weller M
Cell Death Differ; 2008 Apr; 15(4):718-29. PubMed ID: 18202704
[TBL] [Abstract][Full Text] [Related]
36. Targeting cancer stem cells with p53 modulators.
Zhang Z; Liu L; Gomez-Casal R; Wang X; Hayashi R; Appella E; Kopelovich L; DeLeo AB
Oncotarget; 2016 Jul; 7(29):45079-45093. PubMed ID: 27074569
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
Wiman KG
Oncogene; 2010 Jul; 29(30):4245-52. PubMed ID: 20498645
[TBL] [Abstract][Full Text] [Related]
38. PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells.
Magrini R; Russo D; Ottaggio L; Fronza G; Inga A; Menichini P
J Cell Biochem; 2008 Aug; 104(6):2363-73. PubMed ID: 18442053
[TBL] [Abstract][Full Text] [Related]
39. Restoring p53-dependent tumor suppression.
Wang W; Rastinejad F; El-Deiry WS
Cancer Biol Ther; 2003; 2(4 Suppl 1):S55-63. PubMed ID: 14508081
[TBL] [Abstract][Full Text] [Related]
40. An inverse docking approach for identifying new potential anti-cancer targets.
Grinter SZ; Liang Y; Huang SY; Hyder SM; Zou X
J Mol Graph Model; 2011 Apr; 29(6):795-9. PubMed ID: 21315634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]